DUBLIN – Morphosys AG took a significant step toward realizing its ambition to begin marketing its first product by mid-next year, as its CD19-directed antibody, tafasitamab (MOR-208), hit the primary endpoint of a pivotal phase II trial in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).